Cibinqo (
generic name: abrocitinib) can be prescribed to treat
moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
Atopic dermatitis is a long-term inflammatory skin condition that can involve a weakened skin barrier, intense itch, redness, and repeated flares. For some people, symptoms spread beyond a few small patches and start affecting sleep, work, and social life.
Cibinqo is an oral, once‑daily tablet designed to calm immune signals that drive inflammation and itch across the whole body, not only in one spot. It belongs to the
JAK inhibitors drug class, which reduces overactive inflammatory messaging inside immune cells. Because immune signaling is also part of infection defense, a prescriber usually reviews infection history and may order blood tests before and during treatment.
Dosage
The dosage and treatment regimen will be determined by a doctor only. Cibinqo is taken by mouth once daily and should be
swallowed whole with water. The tablet should not be split, crushed, or chewed because this can change how the dose is delivered.
The usually recommended starting dose is 100 mg or 200 mg once daily, depending on severity and the treatment plan. Some patients may need a lower starting dose. Examples include people aged 65 years or older, certain medical histories, moderate-to-severe kidney dysfunction, or people taking specific interacting medicines. In those situations, a doctor may select 50 mg or 100 mg once daily.
Cibinqo can be taken with or without food. If nausea occurs, taking it with food may help. After starting treatment, a doctor may adjust the dose based on response, side effects, and blood test results, and may stop treatment if there is still no improvement after 24 weeks.
Storage
Cibinqo should be kept in a closed place, out of the reach and sight of children and infants. The medicine should not be used after the expiry date printed on the package, which refers to the last day of that month.
There are no special storage conditions, and it is recommended to store the tablets at room temperature. Keeping the tablets in the original pack can help protect them from moisture and mix‑ups. For bottle packs, the shelf life after first opening is 45 days. It helps to note the opening date and keep the bottle tightly closed between doses.
Storage in a dry cabinet is preferred rather than a bathroom where humidity is higher. Unused or expired tablets should be disposed of according to pharmacy guidance rather than saved for later use.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.
The patient information leaflet includes full details about correct use, storage, and possible side effects. It is important to read and understand this information before starting treatment.
Most people who use Cibinqo do not experience serious side effects. Doctors prescribe this medicine when they consider the benefits to outweigh the possible risks.
Common side effects:
- Nausea
- Headache
- Dizziness
- Acne
- Cold sores or other herpes infections
- Increased levels of certain enzymes in blood tests.
Serious side effects requiring immediate medical attention:
- Shingles, with a painful blistering rash and fever
- Blood clots, with symptoms such as chest pain, shortness of breath, or a swollen painful leg.
Not all possible side effects are listed here. If any side effect becomes severe or worrying, medical advice should be sought.
Cibinqo is indicated for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. This form of dermatitis can affect large areas of skin and can interfere with daily activities.
- Persistent itching that may be severe
- Red, inflamed skin patches
- Dry or cracked skin
- Thickened skin from repeated scratching
- Sleep disturbance caused by itching
- Reduced quality of life due to visible skin changes
Systemic therapy is usually considered when topical treatments do not provide adequate control. A doctor decides if this treatment is appropriate based on overall health and medical history.